- vital immunity (Nasdaq:IBRX) on Tuesday that it intends to offer and sell shares of its common stock in an underwritten public offering.
- ImmunityBio intends to use the net proceeds to advance its continued commercialization of ANKTIVA for the treatment of unresponsive, non-muscle-invasive BCG.
https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png
Source link
2024-12-10 21:27:52